Clinical Trial Update: A Study to Compare Immune Response of V503 to Gardasil in 16- to 26-year-old Men (V503-020) [Phase 3]

View source ↗

Summary

Phase 3 study comparing immune response of V503 to Gardasil in 16- to 26-year-old men; completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Genital Warts
• Human Papillomavirus Infection
• Papilloma Viral Infection

Drugs mentioned

• Gardasil (human papillomavirus vaccine)
• V503

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Papilloma Viral Infection | Phase 3 | Status: COMPLETED | Results posted: 2018-11-01